[go: up one dir, main page]

Zolkind et al., 2017 - Google Patents

Checkpoint immunotherapy in head and neck cancers

Zolkind et al., 2017

View PDF
Document ID
4557606626306146694
Author
Zolkind P
Uppaluri R
Publication year
Publication venue
Cancer and Metastasis Reviews

External Links

Snippet

Checkpoint inhibitors have recently gained FDA approval for the treatment of cisplatin- resistant recurrent and metastatic head and neck squamous cell carcinoma (HNSCC) by outperforming standard of care chemotherapy and inducing durable responses in a subset …
Continue reading at pmc.ncbi.nlm.nih.gov (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants

Similar Documents

Publication Publication Date Title
Zolkind et al. Checkpoint immunotherapy in head and neck cancers
Hou et al. Navigating CAR-T cells through the solid-tumour microenvironment
Zhang et al. Advances in cancer immunotherapy: historical perspectives, current developments, and future directions
Prieto et al. Immunological landscape and immunotherapy of hepatocellular carcinoma
Wang et al. The resistance mechanisms of lung cancer immunotherapy
Ferris Immunology and immunotherapy of head and neck cancer
Guo et al. Combined TIM-3 blockade and CD137 activation affords the long-term protection in a murine model of ovarian cancer
Whiteside Head and neck carcinoma immunotherapy: facts and hopes
Jia et al. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects
Narita et al. The key role of IL-6–arginase cascade for inducing dendritic cell–dependent CD4+ T cell dysfunction in tumor-bearing mice
Guo et al. Combined Trabectedin and anti-PD1 antibody produces a synergistic antitumor effect in a murine model of ovarian cancer
Casares et al. A peptide inhibitor of FOXP3 impairs regulatory T cell activity and improves vaccine efficacy in mice
Coukos et al. Opportunities in immunotherapy of ovarian cancer
Mahmoud et al. Immune surveillance in melanoma: From immune attack to melanoma escape and even counterattack
Grenier et al. Combination immunotherapy: taking cancer vaccines to the next level
Yu et al. Current status and perspective of tumor immunotherapy for head and neck squamous cell carcinoma
Kroon et al. Radiotherapy and cisplatin increase immunotherapy efficacy by enabling local and systemic intratumoral T-cell activity
Knutson et al. RETRACTED ARTICLE: Targeted immune therapy of ovarian cancer
US11229668B2 (en) Maximizing T-cell memory and compositions and methods therefor
Rodriguez-Garcia et al. T-cell target antigens across major gynecologic cancers
Krishnan et al. Immunotherapy in ovarian cancer
Kandalaft et al. Tumor immune surveillance and ovarian cancer: lessons on immune mediated tumor rejection or tolerance
Heumann et al. Next-generation immunotherapy for pancreatic ductal adenocarcinoma: navigating pathways of immune resistance
Franks et al. New anticancer immunotherapies
Aris et al. Immunomodulatory monoclonal antibodies in combined immunotherapy trials for cutaneous melanoma